HC Wainwright Equities Analysts Reduce Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at HC Wainwright cut their Q2 2024 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Tuesday, April 30th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.24) per share for the quarter, down from their prior forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.41) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.05.

X4 Pharmaceuticals Stock Performance

XFOR opened at $1.15 on Thursday. The company has a current ratio of 5.34, a quick ratio of 5.34 and a debt-to-equity ratio of 1.07. The company’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $0.93. X4 Pharmaceuticals has a 1-year low of $0.57 and a 1-year high of $2.58. The company has a market cap of $193.13 million, a price-to-earnings ratio of -1.92 and a beta of 0.51.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in shares of X4 Pharmaceuticals by 38.8% in the fourth quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock valued at $40,000 after purchasing an additional 13,328 shares during the last quarter. Barclays PLC grew its position in X4 Pharmaceuticals by 334.8% during the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after buying an additional 294,255 shares during the period. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals during the third quarter valued at about $678,000. Stonepine Capital Management LLC grew its position in X4 Pharmaceuticals by 14.5% during the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock valued at $5,748,000 after buying an additional 668,422 shares during the period. Finally, Kingdon Capital Management L.L.C. grew its position in X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after buying an additional 1,500,000 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the transaction, the chief financial officer now owns 52,500 shares in the company, valued at $53,025. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Paula Ragan sold 49,678 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $43,716.64. Following the completion of the sale, the chief executive officer now owns 765,068 shares in the company, valued at $673,259.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam S. Mostafa sold 27,721 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the sale, the chief financial officer now owns 52,500 shares of the company’s stock, valued at approximately $53,025. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 185,708 shares of company stock worth $170,428. Insiders own 1.08% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.